Clinical Trial Update: Survey on Long-Term Use of ORENCIA® Intravenous Infusion 250mg

View source ↗

Summary

This document reports the completed results of a long-term use survey evaluating intravenous abatacept (ORENCIA) 250 mg in patients with rheumatoid arthritis.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Rheumatoid Arthritis

Drugs mentioned

• Orencia (abatacept) (abatacept)

Snippet

Sponsor: Bristol-Myers Squibb | Conditions: Rheumatoid Arthritis | Status: COMPLETED